

1. How many patients have been treated (for any condition) in the last 3 months with the following products:

Baclofen
Tizanidine
Dantrolene sodium
Diazepam
Sativex
Gabapentin
Botox
Dysport
Xeomin

The Trust does not currently have an electronic prescribing system and is therefore unable to provide data in relation to the number of patients treated with the list of medicines provided.

2. For patients treated for Multiple Sclerosis in the last 3 months, how many patients have been treated with the following products:

Baclofen – information not available
Tizanidine - information not available
Dantrolene Sodium - information not available
Diazepam - information not available
***Sativex** - 24 patients prescribed Sativex have their medication managed by Pharmacy in Belfast Trust.
Gabapentin - information not available
Botox - information not available
Dysport - information not available
Xeomin - information not available

3. For patients admitted for Stroke in the last 3 months, how many patients have been treated with the following products:

The Trust does not currently have an electronic prescribing system and is therefore unable to provide data in relation to the number of patients treated with the list of medicines provided.

4. For patients admitted for Spinal or Brain Trauma in the last 3 months, how many patients have been treated with the following products:

The Trust does not currently have an electronic prescribing system and is therefore unable to provide data in relation to the number of patients treated with the list of medicines provided. However, two of our consultants have provided approximate numbers as follows:

Spinal

Baclofen <40
 Tizanidine <20
 Dantrolene sodium
 Gabapentin <10
 Botox
 Dysport 2-5
 Xeomin

Acquired Brain Injury

Our Regional Acquired Brain Injury Unit has not prescribed Dantrolene Sodium for years. Very little Xeomin and Botox use, approximately two patients (either stroke or brain trauma) each.

- 5. Within your trust, how many patients have been treated (with any medication or procedure) in the past 12 months for the following conditions:**

Spinal

Approximately 60-70

Stroke

Stroke	June 20 – June 21
Total number of confirmed strokes	953
Number of patient receiving Lysis	146
Number of patient receiving Thrombectomy	136

Multiple Sclerosis

The figures for the infusions administered and blood testing reflects workload in Belfast Trust irrespective of patients Trust of residence.

Intravenous infusions administered by the MS Nursing Team in Belfast Trust = ~1200 over a 1 year period (this includes the administration of Ocrelizumab, Natalizumab and Alemtuzumab).

Blood monitoring carried out in Belfast Trust by the MS Nursing Team alone for patients with MS – 1261 blood tests.

We would also manage the care of patients on disease modifying treatments who reside in other Trusts. The following figures reflect Belfast Trust resident patients as requested.

Copaxone (Glatiramer Acetate) - 34
Rebif 22 (Interferon beta 1a) – 7
Rebif 44 (Interferon beta 1a) – 11
Betaferon (Interferon beta 1b) – 2
Avonex (Interferon beta 1a) – 29
Plegridy (Peginterferon beta 1b) – 9
Extavia (Interferon beta 1b) – 1
Tysabri (Natalizumab) – 38
Gilenya (Fingolimod) – 19
Aubagio (Teriflunomide) – 53
(Mavenclad) Cladribine – 6
Tecfidera (Dimethyl Fumarate) – 138
Ocrelizumab – 54

Total No. of Patients on Treatment – 401

Total No. of Treatment Suspensions – 8

Overall Total of Patients on Treatment and Treatment Suspensions – 409

Brain Trauma

Please see attached figures for Brain Trauma Inpatient admissions.